Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental

Detalhes bibliográficos
Autor(a) principal: Santos, José Gilmar Costa
Data de Publicação: 2016
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFS
Texto Completo: http://ri.ufs.br/jspui/handle/riufs/9805
Resumo: Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is a global public health problem and is considered one of the deadliest infectious diseases of the world. It is estimated that about one third of the world population is infected. TB in Central Nervous System (CNS) is one of the most severe forms of the disease, more common in children aged six months to five years old and among individuals with immunosuppression, particularly those with Acquired Immunodeficiency Syndrome (AIDS). Neurotuberculosis (NTB) is associated with a high rate of mortality in children and permanent neurological sequelae in many survivors. Currently, the way to prevent TB is BCG (Bacilo Calmette-Guérin) vaccination, however, it has limitations because it only protects children and only prevents severe forms of TB, besides presenting variable protection of 0-75%. This shows the need to develop a more effective vaccine to fight TB. One of the most promising alternatives for TB is the DNA-hsp65 vaccine, made of a plasmid DNA containing the gene encoding the heat shock protein 65 kDa of mycobacteria (M. leprae). Although, it has not studied the protective effect of DNA-hsp65 vaccine against TB in the CNS, which is the most severe form of the disease and compromises the neural tissue. Thus, we evaluated the prophylactic effect of DNA-hsp65 vaccine in experimental neurotuberculosis. C57BL/6 mice were used by three experimental groups, where one of them was immunized only with plasmideal pVAX vector (vector group) by intramuscular administration of three doses every two weeks, another group received only PBS (PBS group) and the third group DNA was immunized with hsp65-pVAX plasmideal (vaccinated group). Thirty days after the last dose, the animals of each group were challenged with H37Rv laboratorial strain of Mycobacterium tuberculosis intracerebroventricularly by stereotaxy. Thirty days after the challenge with the bacilli, the mice were sacrificed and their brains and lungs removed. These organs were analyzed using histological sections stained with hematoxylin and eosin. It was also determined amounts of colony forming units (CFU) present in the brains of animals in all groups. The results show that animals of the vaccinated group exhibited brain and lung with discrete lesions of the vector and PBS groups. Furthermore, we noticed a reduced number of bacilli in the brains of animals in the vaccinated group. Therefore, our results suggest that DNA-hsp65 vaccine (pVAX-hsp65) is promising in the prevention of injuries caused by bacillus in the CNS.
id UFS-2_d0c59b4ef0e48a2173e1f5c108e373dd
oai_identifier_str oai:ufs.br:riufs/9805
network_acronym_str UFS-2
network_name_str Repositório Institucional da UFS
repository_id_str
spelling Santos, José Gilmar CostaSouza, Patrícia Rodrigues Marques deLucca Junior, Waldecy de2018-11-23T11:36:22Z2018-11-23T11:36:22Z2016-03-04SANTOS, José Gilmar Costa. Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental. 2016. 60 f. Dissertação (Mestrado em Biologia Parasitária) - Universidade Federal de Sergipe, São Cristóvão, SE, 2016.http://ri.ufs.br/jspui/handle/riufs/9805Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is a global public health problem and is considered one of the deadliest infectious diseases of the world. It is estimated that about one third of the world population is infected. TB in Central Nervous System (CNS) is one of the most severe forms of the disease, more common in children aged six months to five years old and among individuals with immunosuppression, particularly those with Acquired Immunodeficiency Syndrome (AIDS). Neurotuberculosis (NTB) is associated with a high rate of mortality in children and permanent neurological sequelae in many survivors. Currently, the way to prevent TB is BCG (Bacilo Calmette-Guérin) vaccination, however, it has limitations because it only protects children and only prevents severe forms of TB, besides presenting variable protection of 0-75%. This shows the need to develop a more effective vaccine to fight TB. One of the most promising alternatives for TB is the DNA-hsp65 vaccine, made of a plasmid DNA containing the gene encoding the heat shock protein 65 kDa of mycobacteria (M. leprae). Although, it has not studied the protective effect of DNA-hsp65 vaccine against TB in the CNS, which is the most severe form of the disease and compromises the neural tissue. Thus, we evaluated the prophylactic effect of DNA-hsp65 vaccine in experimental neurotuberculosis. C57BL/6 mice were used by three experimental groups, where one of them was immunized only with plasmideal pVAX vector (vector group) by intramuscular administration of three doses every two weeks, another group received only PBS (PBS group) and the third group DNA was immunized with hsp65-pVAX plasmideal (vaccinated group). Thirty days after the last dose, the animals of each group were challenged with H37Rv laboratorial strain of Mycobacterium tuberculosis intracerebroventricularly by stereotaxy. Thirty days after the challenge with the bacilli, the mice were sacrificed and their brains and lungs removed. These organs were analyzed using histological sections stained with hematoxylin and eosin. It was also determined amounts of colony forming units (CFU) present in the brains of animals in all groups. The results show that animals of the vaccinated group exhibited brain and lung with discrete lesions of the vector and PBS groups. Furthermore, we noticed a reduced number of bacilli in the brains of animals in the vaccinated group. Therefore, our results suggest that DNA-hsp65 vaccine (pVAX-hsp65) is promising in the prevention of injuries caused by bacillus in the CNS.A tuberculose (TB) é causada pelo Mycobacterium tuberculosis e representa um problema de saúde pública global, sendo considerada uma das doenças transmissíveis mais mortais do mundo. Estima-se que cerca de um terço da população mundial esteja infectada. A TB no Sistema Nervoso Central (SNC) é uma das formas mais graves da doença, sendo mais incidente em crianças de seis meses a cinco anos de idade e entre os indivíduos com imunodepressão, particularmente os portadores da Síndrome da Imunodeficiência Adquirida (AIDS). A Neurotuberculose (NTB) está associada a uma alta taxa de mortalidade em crianças e permanentes sequelas neurológicas em muitos sobreviventes. Atualmente, a forma de prevenção à TB é a vacina BCG (Bacilo Calmette-Guérin), porém, a mesma apresenta limitações, pois protege apenas as crianças e previne somente as formas graves de TB, além de apresentar proteção variável de 0 a 75%. Isso aponta a necessidade do desenvolvimento de uma vacina mais efetiva para o combate da TB. Uma das alternativas mais promissoras para o combate da TB é a vacina de DNA-hsp65, constituída por um plasmídeo de DNA contendo o gene que codifica a proteína de choque térmico de 65 kDa de micobactéria (M. leprae). Ainda não foi estudado o efeito protetor da vacina de DNA-hsp65 contra a TB no SNC, que é a forma mais grave da doença e compromete o tecido neural. Dessa forma, avaliamos o efeito profilático da vacina de DNA-hsp65 na neurotuberculose experimental. Foram utilizados camundongos C57BL/6 através de três grupos experimentais, onde um deles foi imunizado apenas com o vetor plasmideal pVAX (Grupo Vetor) através da administração de três doses quinzenais intramusculares, outro grupo recebeu apenas PBS (Grupo PBS) e o terceiro grupo foi imunizado com o DNA plasmideal pVAX-hsp65 (Grupo Vacinado). Trinta dias após a última dose, os animais de cada grupo foram desafiados com a cepa laboratorial H37Rv de Mycobacterium tuberculosis via intracerebroventricular através de estereotaxia. Passados trinta dias do desafio com o bacilo, os camundongos foram sacrificados e foram removidos cérebro e pulmão. Esses órgãos foram analisados através de cortes histológicos corados com hematoxilina e eosina. Também foram determinadas as quantidades de unidades formadoras de colônias (UFC) presentes nos cérebros dos animais de todos os grupos. Os resultados demonstram que os animais do grupo vacinado apresentaram cérebro e pulmão com lesões mais discretas do que os grupos vetor e PBS. Além disso, percebemos um número reduzido de bacilos nos cérebros dos animais do grupo vacinado. Portanto, nossos resultados sugerem que a vacina de DNA-hsp65 (pVAX-hsp65) é promissora na prevenção das lesões causadas pelo bacilo no SNC.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESSão Cristóvão, SEporTuberculoseVacinaçãoDoenças do sistema nervoso centralNeurotuberculoseProfilaxiaPreventionTuberculosisCentral nervous systemVaccinationCIENCIAS BIOLOGICAS::PARASITOLOGIAAvaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimentalEvaluation of the prophylactic action of the DNA-hsp65 vaccine in neurotuberculosis experimentalinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisPós-Graduação em Biologia ParasitáriaUniversidade Federal de Sergipereponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessTEXTJOSE_GILMAR_COSTA_SANTOS.pdf.txtJOSE_GILMAR_COSTA_SANTOS.pdf.txtExtracted texttext/plain101503https://ri.ufs.br/jspui/bitstream/riufs/9805/3/JOSE_GILMAR_COSTA_SANTOS.pdf.txt5a91ce5d22209e86e56670d949f87d64MD53THUMBNAILJOSE_GILMAR_COSTA_SANTOS.pdf.jpgJOSE_GILMAR_COSTA_SANTOS.pdf.jpgGenerated Thumbnailimage/jpeg1265https://ri.ufs.br/jspui/bitstream/riufs/9805/4/JOSE_GILMAR_COSTA_SANTOS.pdf.jpg3343419dfc35bcdc9f4ca4e6d27df78dMD54ORIGINALJOSE_GILMAR_COSTA_SANTOS.pdfJOSE_GILMAR_COSTA_SANTOS.pdfapplication/pdf1206310https://ri.ufs.br/jspui/bitstream/riufs/9805/2/JOSE_GILMAR_COSTA_SANTOS.pdfb28cb733571974234efc1d24d03ad928MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81475https://ri.ufs.br/jspui/bitstream/riufs/9805/1/license.txt098cbbf65c2c15e1fb2e49c5d306a44cMD51riufs/98052018-11-23 08:36:22.584oai:ufs.br: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2018-11-23T11:36:22Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false
dc.title.pt_BR.fl_str_mv Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
dc.title.alternative.eng.fl_str_mv Evaluation of the prophylactic action of the DNA-hsp65 vaccine in neurotuberculosis experimental
title Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
spellingShingle Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
Santos, José Gilmar Costa
Tuberculose
Vacinação
Doenças do sistema nervoso central
Neurotuberculose
Profilaxia
Prevention
Tuberculosis
Central nervous system
Vaccination
CIENCIAS BIOLOGICAS::PARASITOLOGIA
title_short Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
title_full Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
title_fullStr Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
title_full_unstemmed Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
title_sort Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental
author Santos, José Gilmar Costa
author_facet Santos, José Gilmar Costa
author_role author
dc.contributor.author.fl_str_mv Santos, José Gilmar Costa
dc.contributor.advisor1.fl_str_mv Souza, Patrícia Rodrigues Marques de
dc.contributor.advisor-co1.fl_str_mv Lucca Junior, Waldecy de
contributor_str_mv Souza, Patrícia Rodrigues Marques de
Lucca Junior, Waldecy de
dc.subject.por.fl_str_mv Tuberculose
Vacinação
Doenças do sistema nervoso central
Neurotuberculose
Profilaxia
topic Tuberculose
Vacinação
Doenças do sistema nervoso central
Neurotuberculose
Profilaxia
Prevention
Tuberculosis
Central nervous system
Vaccination
CIENCIAS BIOLOGICAS::PARASITOLOGIA
dc.subject.eng.fl_str_mv Prevention
Tuberculosis
Central nervous system
Vaccination
dc.subject.cnpq.fl_str_mv CIENCIAS BIOLOGICAS::PARASITOLOGIA
description Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is a global public health problem and is considered one of the deadliest infectious diseases of the world. It is estimated that about one third of the world population is infected. TB in Central Nervous System (CNS) is one of the most severe forms of the disease, more common in children aged six months to five years old and among individuals with immunosuppression, particularly those with Acquired Immunodeficiency Syndrome (AIDS). Neurotuberculosis (NTB) is associated with a high rate of mortality in children and permanent neurological sequelae in many survivors. Currently, the way to prevent TB is BCG (Bacilo Calmette-Guérin) vaccination, however, it has limitations because it only protects children and only prevents severe forms of TB, besides presenting variable protection of 0-75%. This shows the need to develop a more effective vaccine to fight TB. One of the most promising alternatives for TB is the DNA-hsp65 vaccine, made of a plasmid DNA containing the gene encoding the heat shock protein 65 kDa of mycobacteria (M. leprae). Although, it has not studied the protective effect of DNA-hsp65 vaccine against TB in the CNS, which is the most severe form of the disease and compromises the neural tissue. Thus, we evaluated the prophylactic effect of DNA-hsp65 vaccine in experimental neurotuberculosis. C57BL/6 mice were used by three experimental groups, where one of them was immunized only with plasmideal pVAX vector (vector group) by intramuscular administration of three doses every two weeks, another group received only PBS (PBS group) and the third group DNA was immunized with hsp65-pVAX plasmideal (vaccinated group). Thirty days after the last dose, the animals of each group were challenged with H37Rv laboratorial strain of Mycobacterium tuberculosis intracerebroventricularly by stereotaxy. Thirty days after the challenge with the bacilli, the mice were sacrificed and their brains and lungs removed. These organs were analyzed using histological sections stained with hematoxylin and eosin. It was also determined amounts of colony forming units (CFU) present in the brains of animals in all groups. The results show that animals of the vaccinated group exhibited brain and lung with discrete lesions of the vector and PBS groups. Furthermore, we noticed a reduced number of bacilli in the brains of animals in the vaccinated group. Therefore, our results suggest that DNA-hsp65 vaccine (pVAX-hsp65) is promising in the prevention of injuries caused by bacillus in the CNS.
publishDate 2016
dc.date.issued.fl_str_mv 2016-03-04
dc.date.accessioned.fl_str_mv 2018-11-23T11:36:22Z
dc.date.available.fl_str_mv 2018-11-23T11:36:22Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv SANTOS, José Gilmar Costa. Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental. 2016. 60 f. Dissertação (Mestrado em Biologia Parasitária) - Universidade Federal de Sergipe, São Cristóvão, SE, 2016.
dc.identifier.uri.fl_str_mv http://ri.ufs.br/jspui/handle/riufs/9805
identifier_str_mv SANTOS, José Gilmar Costa. Avaliação da ação profilática da vacina de DNA-hsp65 na neurotuberculose experimental. 2016. 60 f. Dissertação (Mestrado em Biologia Parasitária) - Universidade Federal de Sergipe, São Cristóvão, SE, 2016.
url http://ri.ufs.br/jspui/handle/riufs/9805
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.program.fl_str_mv Pós-Graduação em Biologia Parasitária
dc.publisher.initials.fl_str_mv Universidade Federal de Sergipe
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFS
instname:Universidade Federal de Sergipe (UFS)
instacron:UFS
instname_str Universidade Federal de Sergipe (UFS)
instacron_str UFS
institution UFS
reponame_str Repositório Institucional da UFS
collection Repositório Institucional da UFS
bitstream.url.fl_str_mv https://ri.ufs.br/jspui/bitstream/riufs/9805/3/JOSE_GILMAR_COSTA_SANTOS.pdf.txt
https://ri.ufs.br/jspui/bitstream/riufs/9805/4/JOSE_GILMAR_COSTA_SANTOS.pdf.jpg
https://ri.ufs.br/jspui/bitstream/riufs/9805/2/JOSE_GILMAR_COSTA_SANTOS.pdf
https://ri.ufs.br/jspui/bitstream/riufs/9805/1/license.txt
bitstream.checksum.fl_str_mv 5a91ce5d22209e86e56670d949f87d64
3343419dfc35bcdc9f4ca4e6d27df78d
b28cb733571974234efc1d24d03ad928
098cbbf65c2c15e1fb2e49c5d306a44c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)
repository.mail.fl_str_mv repositorio@academico.ufs.br
_version_ 1802110678847193088